188 related articles for article (PubMed ID: 18185958)
21. Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
Abut E; Yaşar B; Güveli H; Bölükbaş C; Bölükbaş FF; Dalay AR; Kurdaş OO
Scand J Gastroenterol; 2010 Jun; 45(6):677-83. PubMed ID: 20334478
[TBL] [Abstract][Full Text] [Related]
22. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis.
Ricevuti G; Mazzone A; Uccelli E; Gazzani G; Fregnan GB
Thorax; 1988 Aug; 43(8):585-90. PubMed ID: 3051508
[TBL] [Abstract][Full Text] [Related]
23. [Novel approach to respiratory pharmacology--pharmacological basis of cough, sputum and airway clearance].
Miyata T
Yakugaku Zasshi; 2003 Dec; 123(12):987-1006. PubMed ID: 14689863
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study).
Marchioni CF; Polu JM; Taytard A; Hanard T; Noseda G; Mancini C
Int J Clin Pharmacol Ther; 1995 Nov; 33(11):612-8. PubMed ID: 8688986
[TBL] [Abstract][Full Text] [Related]
25. Use of mucolytics in COPD: A Delphi consensus study.
Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
[TBL] [Abstract][Full Text] [Related]
26. Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial.
Dal Negro RW; Visconti M
Pulm Pharmacol Ther; 2016 Dec; 41():48-51. PubMed ID: 27651323
[TBL] [Abstract][Full Text] [Related]
27. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
Moretti M; Bottrighi P; Dallari R; Da Porto R; Dolcetti A; Grandi P; Garuti G; Guffanti E; Roversi P; De Gugliemo M; Potena A;
Drugs Exp Clin Res; 2004; 30(4):143-52. PubMed ID: 15553660
[TBL] [Abstract][Full Text] [Related]
28. Protective role of erdosteine pretreatment on oleic acid-induced acute lung injury.
Erdem A; Gedikli E; Yersal N; Karaismailoglu S; Muftuoglu S; Fadillioglu E; Tuncer M
J Surg Res; 2017 Jun; 213():234-242. PubMed ID: 28601320
[TBL] [Abstract][Full Text] [Related]
29. The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils.
Dal Sasso M; Bovio C; Culici M; Fonti E; Braga PC
Drugs Exp Clin Res; 2002; 28(4):147-54. PubMed ID: 12512232
[TBL] [Abstract][Full Text] [Related]
30. Erdosteine ameliorates neurological outcome and oxidative stress due to ischemia/reperfusion injury in rabbit spinal cord.
Ege E; Ilhan A; Gurel A; Akyol O; Ozen S
Eur J Vasc Endovasc Surg; 2004 Oct; 28(4):379-86. PubMed ID: 15350559
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of erdosteine in the treatment of chronic rhinosinusitis with nasal polyposis - a pilot study.
Hoza J; Salzman R; Starek I; Schalek P; Kellnerova R
Rhinology; 2013 Dec; 51(4):323-7. PubMed ID: 24260764
[TBL] [Abstract][Full Text] [Related]
32. Erdosteine affects eicosanoid production in COPD.
Dal Negro RW; Visconti M; Tognella S; Micheletto C
Int J Clin Pharmacol Ther; 2011 Jan; 49(1):41-5. PubMed ID: 21176724
[TBL] [Abstract][Full Text] [Related]
33. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats.
Fadillioğlu E; Erdoğan H; Söğüt S; Kuku I
J Appl Toxicol; 2003; 23(1):71-4. PubMed ID: 12518339
[TBL] [Abstract][Full Text] [Related]
34. Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.
Dal Negro R; Pozzi E; Cella SG
Pulm Pharmacol Ther; 2018 Dec; 53():80-85. PubMed ID: 30352285
[TBL] [Abstract][Full Text] [Related]
35. The protective effect of erdosteine against cyclosporine A-induced cardiotoxicity in rats.
Selcoki Y; Uz E; Bayrak R; Sahin S; Kaya A; Uz B; Karanfil A; Ozkara A; Akcay A
Toxicology; 2007 Sep; 239(1-2):53-9. PubMed ID: 17689165
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.
Crisafulli E; Coletti O; Costi S; Zanasi E; Lorenzi C; Lucic S; Fabbri LM; Bertini M; Clini EM
Clin Ther; 2007 Sep; 29(9):2001-9. PubMed ID: 18035199
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of erdosteine, a second generation mucolytic agent, in children with acute rhinosinusitis: a randomized, placebo controlled, double-blinded clinical study.
Unuvar E; Tamay Z; Yildiz I; Toprak S; Kilic A; Aydin S; Kilic G; Guler N; Oguz F; Sidal M
Acta Paediatr; 2010 Apr; 99(4):585-9. PubMed ID: 20055782
[TBL] [Abstract][Full Text] [Related]
38. Effects of erdosteine and its metabolites on bacterial adhesiveness.
Braga PC; Dal Sasso M; Sala MT; Gianelle V
Arzneimittelforschung; 1999 Apr; 49(4):344-50. PubMed ID: 10337454
[TBL] [Abstract][Full Text] [Related]
39. Erdosteine enhances mucociliary clearance in rats with and without airway inflammation.
Hosoe H; Kaise T; Ohmori K
J Pharmacol Toxicol Methods; 1998 Oct; 40(3):165-71. PubMed ID: 10334633
[TBL] [Abstract][Full Text] [Related]
40. [Effects of erdosteine on inflammation and fibrosis in rats with pulmonary fibrosis induced by bleomycin].
Erden ES; Kirkil G; Deveci F; Ilhan N; Cobanoğlu B; Turgut T; Muz MH
Tuberk Toraks; 2008; 56(2):127-38. PubMed ID: 18701972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
